Drug intelligence / Profile preview

liposome bupivacaine (bupivacaine liposome) (Pacira BioSciences, 045428)

Development stage
Approved
Lead developer
Pacira BioSciences
Modality
Small Molecules
Administration
Parenteral
01

Overview

Bupivacaine liposome (brand name: Exparel) is a long-acting, extended-release local anesthetic formulation developed by Pacira BioSciences. It utilizes the DepoFoam multivesicular liposomal drug delivery system to encapsulate bupivacaine, a small molecule sodium channel blocker, allowing for controlled release over approximately 72 hours. By inhibiting voltage-gated sodium channels on nerve cell membranes, it prevents the initiation and conduction of nerve impulses, thereby providing prolonged postsurgical analgesia. It is primarily indicated for single-dose infiltration in adults to produce postsurgical local analgesia and as an interscalene brachial plexus nerve block for postsurgical regional analgesia.

Brand names
Exparel
Other names
liposomal bupivacainebupivacaine liposome injectable suspension
02

Targets

SCN9A (Sodium channel protein type 9 subunit alpha)SCN10A (Sodium channel protein type X alpha subunit)SCN11A (NaV1.9)

Beyond the preview

Go deeper on liposome bupivacaine (bupivacaine liposome) (Pacira BioSciences, 045428).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on liposome bupivacaine (bupivacaine liposome) (Pacira BioSciences, 045428).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call